补阳还五汤联合依达拉奉右莰醇注射液治疗急性脑梗死的临床疗效

doi:10.3969/j.issn.1671-7171.2025.08.027

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1273 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the clinical efficacy of Buyang Huanwu Decoction combined with edaravone dexborneol injection in the treatment of acute cerebral infarction (ACI).【Methods】A total of 90 ACI patients were randomly divided into the control group and the observation group, with 45 cases in each group. The control group received edaravone dexborneol injection, while the observation group received BYHWD in addition to the same treatment as the control group. Changes in carotid intima-media thickness (IMT), plaque area, Traditional Chinese Medicine (TCM) syndrome score, neurological deficit [National Institutes of Health Stroke Scale (NIHSS) score], quality of life [Modified Rankin Scale (MRS) score], and serum levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) and neuron-specific enolase (NSE) were compared between the two groups before and after treatment.【Results】 After treatment, the observation group showed significantly lower carotid IMT, plaque area, TCM syndrome score, NIHSS score, mRS score, Lp-PLA2, and NSE levels compared to the control group (P<0.05).【Conclusion】Buyang Huanwu Decoction combined with edaravone dexborneol injection can effectively alleviate arterial lesions, improve TCM symptoms and neurological function, enhance quality of life, and reduce serum Lp-PLA2 and NSE levels in ACI patients, making it worthy of clinical promotion.

Key words： Brain Infarction Acute Disease Buyang Huanwutang Edaravone Treatment Outcome

Received: 10 April 2025

PACS:

R743.33

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Tengxi
	BAO Dangzhen

Cite this article:

ZHU Tengxi,BAO Dangzhen. Therapeutic Effect of Buyang Huanwu Decoction Combined with Edaravone Dexborneol Injection in the Treatment of Acute Cerebral Infarction[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(8): 1388-1390.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.08.027 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I8/1388

[1] 林雅明,吴云虹,肖林婷,等. 依达拉奉右莰醇联合丁苯酞治疗急性脑梗死患者的临床研究[J].中国临床药理学杂志,2023,39(18):2602-2606.
[2] 杨华英,崔娅晖,郑连红,等. 依达拉奉右莰醇联合丁苯酞氯化钠注射液对急性脑梗死患者血清单核细胞趋化蛋白-1、内皮素-1表达的影响[J].中国药业,2024,33(9):135-138.
[3] 孙炎,王刚,刘宏娜,等. 补阳还五汤对机械取栓后急性脑梗死患者的影响及安全性研究[J].中华中医药学刊,2025,43(3):124-128.
[4] 赵伟,钱兴龙,刘宇驰,等. 升阳通督针法联合补阳还五汤治疗急性缺血性脑卒中(气虚血瘀证)的临床观察[J].中国中医急症,2025,34(2):302-306.
[5] 中国中西医结合学会神经科专业委员会.中国脑梗死中西医结合诊治指南(2017)[J].中国中西医结合杂志,2018,38(2):136-144.
[6] 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:201-202.
[7] 吴正欢,史俊,周梦奇,等. 依达拉奉右莰醇注射用浓溶液联合己酮可可碱治疗急性脑梗死的临床研究[J].现代药物与临床,2023,38(3):591-595.
[8] 罗明晶,刘婧,王心怡,等. 依达拉奉右莰醇联合rt-PA治疗急性脑梗死的疗效[J].西部医学,2025,37(2):284-288.
[9] 石岩硕,要凯青,曹格溪,等. 依达拉奉右莰醇联合丁苯酞氯化钠治疗急性脑梗死的系统评价[J].中国医院用药评价与分析,2024,24(5):598-601.
[10] 张丹丹,王益,吴晶,等. 依达拉奉右莰醇静脉滴注治疗急性动脉粥样硬化性脑梗死临床观察[J].山东医药,2024,64(15):52-55.
[11] 崔二平,侯志刚,许伟,等. 依达拉奉右莰醇联合替罗非班辅助综合康复干预治疗老年急性脑梗死的临床疗效[J].中国老年学杂志,2023,43(16):3858-3860.
[12] 田飞,戴红波. 阿替普酶溶栓联合依达拉奉右莰醇治疗急性后循环脑梗死疗效及对神经功能相关因子的影响[J].中国医药导刊,2023,25(2):187-191.
[13] 刘前,邓倩,周静,等. 依达拉奉右莰醇联合阿托伐他汀治疗老年急性脑梗死的临床疗效及对脑血流动力学的影响[J].中国老年学杂志,2023,43(2):276-279.
[14] 王晓辉,蒋锋,常莎,等. 依达拉奉右莰醇治疗血管介入术后急性脑梗死的疗效及对血液流变学和血清Lp-PLA2、NSE水平的影响[J].中国实用神经疾病杂志,2024,27(9):1057-1061.